Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation
Oppenheimer has maintained its Outperform rating for Xeris Biopharma Holdings (XERS). This update indicates continued confidence from the firm in the biopharmaceutical company's performance and future prospects. Investors will likely view this as a positive signal for XERS.
XERS Technical Analysis & Stock Price Forecast
The article provides a technical analysis of Xeris Biopharma Holdings Inc (XERS), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. It details specific metrics like RSI, MACD, and support/resistance levels, noting that XERS is trading below its 60-day and 200-day moving averages. The analysis suggests caution for investors considering the stock, despite some individual "buy" signals within specific moving average periods.
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript
Xeris Biopharma Holdings Inc. reported a Q1 2025 revenue increase of 48%, marking its 14th consecutive quarter of over 20% product revenue growth. The company raised its revenue guidance and saw significant growth in Rekorolev, driven by strategic investments. Despite no updated peak sales guidance for Rekorolev and increased SG&A expenses, Xeris maintains a strong financial position, with positive adjusted EBITDA and FDA approval for an expanded GVO vileDX diagnostic use.
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS)
Beth Hecht, an insider at Xeris Biopharma Holdings Inc (XERS), sold 16,667 shares on April 1, 2026, reducing her holdings to 1,209,840 shares. This transaction follows a pattern of insider selling at the company, with 16 sells and only 1 buy over the past year. The stock was trading at $5.99 on the day of sale, and with a GF Value of $4.53, it is considered significantly overvalued.
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock
Xeris Biopharma (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the company's stock for $99,835.33 on April 1st under a pre-arranged trading plan, reducing her stake by 1.36%. This follows similar sales in February and March. The company recently reported an EPS beat but revenue slightly missed expectations, holding a "Moderate Buy" consensus rating from analysts with an average price target of $10.80.
Xeris Biopharma Approves Inducement Grants for 50,000 Shares to Two New Employees
Xeris Biopharma Holdings, Inc. has approved inducement grants for two new employees, totaling 50,000 shares of Xeris common stock. These stock options, granted on April 3, 2026, are part of the company's strategy to attract and retain talent and will vest over four years, contingent on continued service. The grants were approved by Xeris' Compensation Committee and are issued outside existing equity incentive plans, complying with NASDAQ Listing Rule 5635(c)(4).
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan
Xeris Biopharma Holdings, Inc. officer Beth Hecht sold 16,667 shares of common stock at a weighted average price of $5.9914 per share, totaling approximately $100,000. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Hecht directly owns 1,209,840 shares of the company.
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted restricted stock units for 304,975 shares of common stock to 90 new employees on April 1, 2026. These grants were made under Xeris' Inducement Equity Plan, exclusively for new hires, in compliance with NASDAQ Listing Rule 5635(c)(4). The restricted stock units will vest over three years, contingent on continued employment.
James Aloysius Brady Sells 10,834 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
James Aloysius Brady, a Director at Xeris Biopharma (NASDAQ:XERS), sold 10,834 shares of the company's stock for a total of $60,020.36 on March 30th, reducing his stake by 10.83%. Despite this insider selling, Xeris Biopharma's stock traded up 0.8% at $6.09, with a market capitalization of $1.05 billion, and the company has a "Moderate Buy" consensus rating with an average price target of $10.80. The company recently beat quarterly earnings estimates and saw significant institutional buying from firms like Goldman Sachs, Millennium Management, and RBC.
Tudor Investment Corp ET AL Decreases Stake in Xeris Biopharma Holdings, Inc. $XERS
Tudor Investment Corp ET AL significantly reduced its stake in Xeris Biopharma Holdings, Inc. ($XERS) by 83.1% in the third quarter, selling 187,192 shares. Despite this, other institutions like Voya Investment Management LLC, Calamos Advisors LLC, and Divisadero Street Capital Management LP increased their holdings, with institutional ownership standing at 42.75%. Xeris Biopharma's stock has a "Moderate Buy" consensus rating from analysts, with insider sales totaling 89,908 shares in the last three months.
Brady sells Xeris Biopharma (XERS) shares worth $60,035 By Investing.com
Director James Aloysius Brady of Xeris Biopharma Holdings Inc. sold 10,834 shares for $60,035, although the stock has since risen 14%. Despite the sale, analysts see significant upside potential for XERS, with price targets ranging from $8 to $18, and the company recently reported strong Q4 2025 financial results, surpassing earnings and revenue expectations.
Brady sells Xeris Biopharma (XERS) shares worth $60,035
James Aloysius Brady, a director at Xeris Biopharma Holdings Inc (NASDAQ:XERS), sold 10,834 shares for $60,035 on March 30, 2026, under a pre-arranged trading plan. Despite the sale, the stock has since gained 14%, and analysts express significant upside potential, with price targets ranging from $8 to $18. This follows strong Q4 2025 financial results, where Xeris exceeded earnings and revenue projections, and Barclays reiterated an "Overweight" rating.
Insider Sell: James Brady Sells Shares of Xeris Biopharma Holdin
James Brady, a Director at Xeris Biopharma Holdings Inc (XERS), sold 10,834 shares of the company on March 30, 2026. This transaction leaves him with 89,166 shares. Xeris Biopharma Holdings Inc is trading at $5.54, which is considered significantly overvalued compared to its GF Value of $4.53.
Xeris Biopharma (XERS) director sells 10,834 shares in Rule 10b5-1 trades
Xeris Biopharma Holdings director Brady James Aloysius sold 10,834 shares of common stock at a weighted average price of $5.5414 per share, totaling $60,036. This transaction was conducted under a Rule 10b5-1 trading plan, with individual sales ranging from $5.29 to $5.63. Following the sale, Mr. Aloysius directly holds 89,166 shares in the company.
Brady sells Xeris Biopharma (XERS) shares worth $60,035
Director James Aloysius Brady recently sold 10,834 shares of Xeris Biopharma Holdings Inc (NASDAQ:XERS) for a total of $60,035. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, the stock has since gained 14%, and analysts maintain a positive outlook with price targets ranging from $8 to $18, citing strong financial results and underappreciated market capitalization.
[144] Xeris Biopharma Holdings, Inc. SEC Filing
This article details a Form 144 SEC filing by Xeris Biopharma Holdings, Inc. (XERS) dated March 30, 2026. The filing indicates a proposed sale of 10,834 common shares with an aggregate market value of $58,503.60, acquired as Restricted Stock Units on March 28, 2026. The sale is planned through Morgan Stanley Smith Barney LLC on NASDAQ.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of "Moderate Buy" by Brokerages
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $10.80. The company recently reported Q4 EPS of $0.06, beating expectations, with revenue of $85.8 million, though it maintains a thin net margin and analysts forecast a negative EPS for the current year. Insiders have been net sellers in the last 90 days, while institutional investors hold a significant portion of the stock.
Vanguard (XERS) disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares
The Vanguard Group filed an amended Schedule 13G/A for Xeris Biopharma Holdings Inc. (XERS), reporting 0 shares beneficially owned and 0% of the class. This change follows an internal realignment on January 12, 2026, wherein certain Vanguard subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. The filing was signed by Ashley Grim, Head of Global Fund Administration, on March 27, 2026.
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.4% - What's Next?
Xeris Biopharma (NASDAQ:XERS) shares increased by 5.4% on Thursday, trading at $5.5850 on lighter than average volume. Analysts generally maintain a "Moderate Buy" rating with an average price target of $10.80, despite recent insider share sales and the company's current unprofitability. Xeris reported an EPS beat but a slight revenue miss in their last quarterly earnings.
Revenue per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E
This article focuses on the revenue per share of Xeris Biopharma Holdings, Inc. (LSE:0A8E). It appears to be a financial data entry from TradingView, providing an overview of the company's financial performance. The content is primarily a listing of financial data fields without specific numbers.
Xeris Biopharma stock faces analyst scrutiny amid pipeline delays and biotech volatility
Xeris Biopharma Holdings Inc (XERS) is under analyst scrutiny due to pipeline delays and sector volatility, despite a strong "buy" consensus from analysts with an average price target of $6.58. The company focuses on endocrine and metabolic disorders, with key products like Glucagon RT and Gvoke driving revenue, and is approaching profitability with a solid cash position. Risks include intensifying competition, regulatory hurdles, and potential supply chain disruptions, but upcoming catalysts like Recorlev approval and pediatric label expansions offer growth potential.
Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch exercised stock options to acquire 48,898 shares of common stock on March 12, 2026, at exercise prices of $4.09 and $3.94 per share. These options, granted under the company’s 2018 Stock Option/Stock Issuance Plan, were fully vested. Following these transactions, McCulloch directly holds 1,777,725 common shares and indirectly holds 25,000 shares through his spouse.
Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS
Divisadero Street Capital Management LP has invested $3.31 million in Xeris Biopharma Holdings, Inc. by acquiring 406,334 shares, giving them a 0.24% stake. Other institutional investors like Geode Capital and Goldman Sachs also increased their holdings, bringing total institutional ownership to 42.75%. Despite positive EPS in the last quarter, the company faces insider selling and a negative return on equity, though analysts maintain a "Moderate Buy" rating with an average price target of $10.80.
Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlook
Xeris Biopharma shares rose almost 3% following better-than-expected Q4 earnings. The company reported a significant increase in total revenue, driven by strong sales of Recorlev and Keveyis, and provided an optimistic financial outlook for 2026.
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance
Xeris Biopharma Holdings (XERS) has reported a move from loss to profit in Q4 and full year 2025 results, along with new 2026 revenue guidance. Despite these positive developments and a significant discount to analyst price targets, the company's recent share price performance has been weak. The article discusses Xeris's valuation, highlighting a fair value estimate of $11.14 against a closing price of $5.81, indicating it is undervalued, but also cautions about execution risk due to its narrow product lineup and the P/S ratio being below the US Pharmaceuticals average.
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance
Xeris Biopharma Holdings (XERS) has garnered attention after achieving profitability in Q4 and FY2025, providing 2026 revenue guidance of US$375 million to US$390 million, and filing a US$40.7 million shelf registration. Despite recent share price declines, the company is considered 47.9% undervalued by analysts, trading at a discount to their fair value estimate of $11.14, and its P/S ratio is below the industry average. Simply Wall St highlights both the growth potential driven by strong margins and scaling sales, as well as the risks associated with its narrow product lineup and potential for high R&D/SG&A expenses to outpace revenue.
Xeris Biopharma (XERS) officer exercises options, lifts share holdings
Xeris Biopharma officer Steven Pieper exercised stock options on March 5, 2026, acquiring 27,891 common shares at $4.09 each and 14,036 common shares at $5.93 each through derivative exercises. These options were granted under company stock option plans in 2018 and 2020, with vesting contingent on continued employment. Following these transactions, Pieper directly owned 1,408,940 common shares of Xeris Biopharma.
Xeris Biopharma Holdings, Inc. Experiences Evaluation Revision Amid Market Dynamics and Performance Trends
Xeris Biopharma Holdings, Inc. has undergone an evaluation revision due to fluctuating market conditions, with its stock currently at $6.04, down from $6.07. Despite short-term challenges, including a year-to-date return of -23.06%, the company has demonstrated resilience with a one-year return of 60.21%, outperforming the S&P 500. Technical indicators show mixed signals, suggesting both bearish and bullish trends depending on the timeframe.
HC Wainwright Forecasts Xeris Biopharma Q1 Earnings
HC Wainwright forecasts Xeris Biopharma (NASDAQ: XERS) to have a Q1 2026 EPS of ($0.03), maintaining a "Buy" rating and a $10 price target. This outlook comes after Xeris reported a Q4 2025 EPS of $0.06, surpassing estimates, with revenues largely meeting expectations. Despite positive sentiment from earnings and analyst ratings, potential headwinds include recent insider selling and ongoing patent litigation risks for its drug Recorlev.
Record 2025 results as Xeris Biopharma (XERS) guides for 30%+ 2026 growth
Xeris Biopharma reported record financial results for the fourth quarter and full year 2025, achieving profitability after a net loss in 2024. The company announced total revenue of $291.8 million for 2025 and provided strong 2026 guidance, projecting total revenue between $375 million and $390 million, representing over 30% growth. This positive outlook is driven by increased sales of products like Recorlev and Gvoke, alongside strategic investments in R&D and SG&A.
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock
Xeris Biopharma insider Beth Hecht sold 16,667 shares of the company's stock for $104,168.75 on March 2nd, reducing her stake by 1.34%. This sale follows earlier transactions in February and January, while the company recently reported strong Q4 earnings, beating analyst expectations, and set an ambitious revenue growth target of over 30% for 2026. The stock currently holds a "Moderate Buy" consensus rating with a target price of $10.08, though it faces potential downside from patent disputes.
A Look At Xeris Biopharma Holdings (XERS) Valuation After Recent Share Price Weakness
Xeris Biopharma Holdings (XERS) has experienced recent share price weakness despite positive annual revenue and net income growth. The stock is currently trading at US$6.12, which is significantly undervalued compared to the average analyst price target and its fair value narrative of $11.14 per share. This suggests a potential opportunity, though future performance depends on successful trials and controlled R&D/SG&A costs.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. announced strong financial results for Q4 and full year 2025, achieving financial self-sustainability for the first time. The company reported significant revenue growth across its three commercial products—Recorlev, Gvoke, and Keveyis—and provided an optimistic revenue outlook for 2026, driven by an expanded commercial team and continued investment in its pipeline asset, XP-8121. Xeris also addressed a recent patent infringement lawsuit concerning Recorlev, expressing confidence in its intellectual property and long-term sales targets.
XERS: Higher 2025–2026 Revenue Guidance Will Support Future Cash Generation
Xeris Biopharma Holdings (XERS) has updated its revenue guidance for 2025 and 2026, projecting higher figures than previously anticipated. Despite this, analysts have lowered their price target to $21.03 from $25.82, primarily due to a reduced assumed future P/E multiple, even though revenue growth and profit margins are expected to improve. The company's intrinsic fair value remains unchanged at $11.14 per share, as the increased revenue growth and net profit margin are offset by the lower P/E multiple.
Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative
Xeris Biopharma Holdings (XERS) achieved profitability in FY 2025 with US$85.8 million in Q4 revenue and US$0.07 basic EPS, translating to a trailing twelve-month net profit of US$0.6 million on US$291.8 million revenue. This shift from a trailing loss in Q4 2024 to profitability in Q4 2025 sets the stage for a debate on the durability of its improving margins and challenges previous bearish narratives despite ongoing concerns about interest coverage and insider selling. The company's revenue growth, driven by key drugs, supports a bullish outlook, with its current valuation significantly below a DCF fair value, though risks remain.
Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - Here's What Happened
Xeris Biopharma (NASDAQ:XERS) experienced a pre-market gap up, with shares opening at $7.08 compared to a previous close of $6.12. The stock, which has a market cap of approximately $1.03 billion, last traded around $6.66 on substantial volume. Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $10.08, despite recent insider share sales by executives and directors totaling over 223,641 shares.
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
Xeris Biopharma Holdings, Inc. announced record financial results for the fourth quarter and full year ended December 31, 2025, with total revenue reaching $85.8 million and $291.8 million, respectively. The company also provided strong full-year 2026 guidance, projecting total revenue between $375 million to $390 million, driven by continued growth in Recorlev, Gvoke, and Keveyis, and investments in their pipeline, particularly XP-8121. Despite increased R&D and SG&A expenses for growth initiatives, Xeris expects improved Adjusted EBITDA and is positioned for a self-funding, sustainable future.
Earnings Flash (XERS) Xeris Biopharma Holdings, Inc. Reports Q4 Revenue $85.8M, vs. FactSet Est of $82.2M
Xeris Biopharma Holdings, Inc. reported Q4 revenue of $85.8 million, surpassing FactSet's estimated $82.2 million. The company also announced a swing to profit in Q4, revenue growth, and provided 2026 revenue guidance ranging from $375 million to $390 million, exceeding FactSet's estimate of $368 million. Additionally, Xeris Biopharma posted a Q4 EPS of $0.06, better than FactSet's estimate of $0.02.
Xeris Biopharma: Q4 Earnings Snapshot
Xeris Biopharma Holdings, Inc. (XERS) reported Q4 earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. The company's revenue of $35.8 million also exceeded analyst forecasts. For the full year, Xeris Biopharma reported a profit of $556,000 and projects full-year revenue between $365 million and $380 million.
Why Are Shares Of Xeris Biopharma Falling Friday?
Shares of Xeris Biopharma Holdings, Inc. are falling after the company announced a patent infringement lawsuit against Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC to protect its drug, Recorlev, from unauthorized generic versions. The lawsuit aims to safeguard its intellectual property until March 2040 and Orphan Drug Exclusivity until December 2028. Despite a 61.30% stock price increase over the last year, the stock is currently trading below key moving averages, signaling a bearish outlook, while the company prepares to report earnings on March 2, 2026, with analysts anticipating an EPS of 4 cents and revenue of $84.17 million.
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a 65% Potential Upside for Investors
Xeris Biopharma Holdings, Inc. (XERS) is presented as a compelling investment opportunity in the biotechnology sector, specializing in chronic endocrine and neurological diseases. Analysts project a potential upside of 65.32%, with an average target price of $11.14, supported by strong revenue growth and a promising product pipeline. Despite mixed technical indicators and the absence of a dividend, the company's focus on growth and innovation makes it attractive for long-term investors.
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event | XERS SEC Filing - Form 8-K
Xeris Biopharma Holdings, Inc. announced that its subsidiaries have filed a patent infringement lawsuit under the Hatch-Waxman Act against two pharmaceutical companies. These companies submitted Abbreviated New Drug Applications (ANDAs) seeking approval for a generic version of RECORLEV® (levoketoconazole). Xeris aims to prevent the manufacture, use, and sale of a generic RECORLEV until its patents expire in March 2040.
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Xeris Biopharma Holdings, Inc. announced that its subsidiaries have filed a patent infringement lawsuit against Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC. The lawsuit, filed under the Hatch-Waxman Act, aims to prevent the manufacture, use, and sale of generic versions of Recorlev® (levoketoconazole) until Xeris's patents expire in March 2040. The action follows Paragraph IV Certification Notice Letters from the ANDA Filers, who stated that Xeris's patents are invalid or would not be infringed.
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Xeris Biopharma's subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit against Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC. The lawsuit, filed under the Hatch-Waxman Act, concerns generic versions of Recorlev® (levoketoconazole) that the defendants sought to approve through Abbreviated New Drug Applications. Xeris is seeking an injunction to prevent the manufacture, use, and sale of these generic versions until its patents expire in March 2040.
[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity
Xeris Biopharma Holdings, Inc. officer Anh Tu Nguyen reported a tax-related transaction where 29,300 shares of common stock were withheld by the company at $6.88 per share. This action covered income tax obligations on vested restricted stock units as of February 24, 2026. Following this disposition, Nguyen directly owns 395,023 shares, with additional indirect holdings through IRAs.
XERS Crosses Below Key Moving Average Level
Shares of Xeris Biopharma Holdings Inc (XERS) have fallen below their 200-day moving average of $6.76, trading as low as $6.41 per share on Thursday. This represents a drop of about 6.5% on the day. The article notes that XERS's 52-week trading range is between $3.58 and $10.08, with the last trade at $6.55.
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by CenterBook Partners LP
CenterBook Partners LP significantly reduced its stake in Xeris Biopharma Holdings, Inc. ($XERS) during the third quarter, selling over 896,000 shares. Despite this, analysts have a "Moderate Buy" consensus rating for XERS with a target price of $10.08, and the stock received a price target increase from Piper Sandler and a new "overweight" rating from Barclays. Insiders have also been net sellers of the stock recently, while institutional investors and hedge funds collectively own 42.75% of the company.
Will Xeris Stock Revisit Its 52-week High?
Xeris Biopharma Holdings Inc. (XERS) entered 2026 with strong commercial momentum after a transformative 2025, driven by its products Recorlev, Gvoke, and Keveyis. The company's product revenue has shown sustained growth, reaching $196.64 million in 2024. Investors are awaiting the full-year 2025 results, with anticipated total revenue of $292 million, following a significant rally in its stock price to a 52-week high of $10.08 in November 2025.
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Xeris Biopharma Holdings, Inc. announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial and operational results for the year 2025 and provide guidance for 2026. Interested parties can pre-register for the call or join the live webcast via provided links, with a replay available on the company's Investor Relations website.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received an average "Moderate Buy" rating from eight analysts, with a 12-month average target price of $10.08. Despite recent insider selling totaling over $2 million, institutional investors, including Vanguard and UBS, have been increasing their positions, resulting in 42.75% institutional ownership. The company, focused on endocrine and orphan diseases, trades near $7.01 with a $1.16 billion market cap.
